

James Chih-Hsin Yang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5070242/james-chih-hsin-yang-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

241
papers

20,037
citations

57
h-index

139
g-index

257
ext. papers

24,242
ext. citations

5.5
avg, IF

6.54
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 241 | Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon Mutations: An Updated Database of 1023 Cases Brief Report.. <i>Frontiers in Oncology</i> , 2022 , 12, 834704 | 5.3 | 1 |
| 240 | Tepotinib Efficacy and Safety in Patients with Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. <i>Clinical Cancer Research</i> , 2021 , | 12.9 | 5 |
| 239 | 457 KEYNOTE-495/KeyImpACT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (NSCLC) 2021 , 9, A485-A485 | | |
| 238 | Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2021 , | 8.9 | 13 |
| 237 | Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. <i>Lung Cancer</i> , 2021 , 154, 113-117 | 5.9 | 2 |
| 236 | Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9008-9008 | 2.2 | 12 |
| 235 | HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS9139-TPS9139 ¹ | 2.2 | 13 |
| 234 | Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9077-9077 | 2.2 | 13 |
| 233 | Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 162-168 | 8.9 | 26 |
| 232 | Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive -mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 992-1002 ^{12,9} | 12.9 | 17 |
| 231 | Benefits and limitations of real-world evidence: lessons from mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2021 , 17, 965-977 | 3.6 | 10 |
| 230 | Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in -Mutant Non-Small Cell Lung Cancer Cells. <i>Cancers</i> , 2021 , 13, | 6.6 | 2 |
| 229 | Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With -Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100114 | 1.4 | 3 |
| 228 | Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100140 | 1.4 | 2 |
| 227 | Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100142 | 1.4 | |
| 226 | CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2021 , 41, 1231-1242 | 2.3 | 7 |
| 225 | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3391-3402 | 2.2 | 62 |

| | | | |
|-----|---|------|-----|
| 224 | Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). <i>Future Oncology</i> , 2021 , 17, 4237-4247 | 3.6 | 3 |
| 223 | Real-world insights into patients with advanced NSCLC and MET alterations. <i>Lung Cancer</i> , 2021 , 159, 96-106 | 5.9 | 0 |
| 222 | Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100099 | 1.4 | |
| 221 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020 , 25, 702-711 | 5.7 | 11 |
| 220 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 1132-1143 | 35.1 | 66 |
| 219 | Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2369-2379 | 2.2 | 160 |
| 218 | Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020 , 122, 1324-1332 | 8.7 | 11 |
| 217 | Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1817-1826 | 3.2 | 4 |
| 216 | Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 803-815 | 8.9 | 77 |
| 215 | Precision Management of Advanced Non-Small Cell Lung Cancer. <i>Annual Review of Medicine</i> , 2020 , 71, 117-136 | 17.4 | 52 |
| 214 | Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology</i> , 2020 , 21, 373-386 | 21.7 | 148 |
| 213 | The Role of Interleukin 1 β in the Pathogenesis of Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100001 | 1.4 | 10 |
| 212 | Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3588-3588 | 2.2 | 2 |
| 211 | KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9001-9001 | 2.2 | 11 |
| 210 | Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9503-9503 | 2.2 | 99 |
| 209 | Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9517-9517 | 2.2 | 12 |
| 208 | Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9574-9574 | 2.2 | 2 |
| 207 | CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS9075-TPS9075 | 2.2 | 2 |

| | | | |
|-----|---|------|----|
| 206 | Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. <i>Cancer Research and Treatment</i> , 2020 , 52, 284-291 | 5.2 | 2 |
| 205 | Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020 , 22, 76-82 | 4.6 | 6 |
| 204 | A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS9631-TPS9631 | 2.2 | 2 |
| 203 | Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020 , 139, 22-27 | 5.9 | 9 |
| 202 | Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 50-61 | 8.9 | 29 |
| 201 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 324-343 | 8.9 | 13 |
| 200 | Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma. <i>Lung Cancer</i> , 2020 , 148, 177-178 | 5.9 | 2 |
| 199 | Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1907-1918 | 8.9 | 36 |
| 198 | The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 17588359209461564 | 5.4 | 3 |
| 197 | A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020 , 38, 99-110 | 4.3 | 25 |
| 196 | The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020 , 59, 96-100 | 3.2 | 5 |
| 195 | A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 91-100 | 8.9 | 17 |
| 194 | The Inhibition of Wnt Restrain KRAS-Driven Metastasis in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020 , 12, | 6.6 | 3 |
| 193 | Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. <i>Lung Cancer</i> , 2019 , 133, 103-109 | 5.9 | 17 |
| 192 | First-line afatinib for the treatment of mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919836374 | 5.4 | 20 |
| 191 | Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 995-1004 | 3.2 | 4 |
| 190 | Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 933-939 | 8.9 | 83 |
| 189 | Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?. <i>Lancet Oncology</i> , <i>The</i> , 2019 , 20, 602-603 | 21.7 | 1 |

| | | | |
|-----|--|------|-----|
| 188 | First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. <i>Lung Cancer</i> , 2019 , 133, 10-19 | 5.9 | 14 |
| 187 | Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 132, 126-131 | 5.9 | 17 |
| 186 | Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 553-559 | 8.9 | 66 |
| 185 | Phase I Study of the Focal Adhesion Kinase Inhibitor BI-853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. <i>Targeted Oncology</i> , 2019 , 14, 57-65 | 5 | 15 |
| 184 | Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. <i>Journal of Nanobiotechnology</i> , 2019 , 17, 89 | 9.4 | 20 |
| 183 | Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study. <i>Clinical Lung Cancer</i> , 2019 , 20, e609-e618 | 4.9 | 9 |
| 182 | Opportunities of circulating tumor DNA in lung cancer. <i>Cancer Treatment Reviews</i> , 2019 , 78, 31-41 | 14.4 | 12 |
| 181 | Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. <i>European Journal of Cancer</i> , 2019 , 117, 107-115 | 7.5 | 18 |
| 180 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. <i>EMBO Molecular Medicine</i> , 2019 , 11, e10581 | 12 | 21 |
| 179 | First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1569-1579 | 4.9 | 24 |
| 178 | Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. <i>Oncologist</i> , 2019 , 24, e1417-e1423 | 5.7 | 13 |
| 177 | Second-line treatment of T790M-negative non-small cell lung cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919890286 | 5.4 | 12 |
| 176 | Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (-)Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. <i>Lung Cancer: Targets and Therapy</i> , 2019 , 10, 125-130 | 2.9 | 5 |
| 175 | 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 124-129 | 8.9 | 137 |
| 174 | Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. <i>International Journal of Cancer</i> , 2019 , 144, 2887-2896 | 7.5 | 32 |
| 173 | Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 230-236 | 3.2 | 5 |
| 172 | Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2018 , 19, e361-e372 | 4.9 | 14 |
| 171 | Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. <i>Cancer Research</i> , 2018 , 78, 3350-3362 | 10.1 | 23 |

| | | | |
|-----|--|------|-----|
| 170 | The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1156-1169 | 3.8 | 30 |
| 169 | Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. <i>Clinical Drug Investigation</i> , 2018 , 38, 319-331 | 3.2 | 12 |
| 168 | Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 210-216 | 13.4 | 277 |
| 167 | The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 792-800 | 8.9 | 15 |
| 166 | Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018 , 19, e465-e479 | 4.9 | 39 |
| 165 | Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 326-331 | 3.2 | 7 |
| 164 | A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, 27-34 | 4.9 | 17 |
| 163 | Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. <i>Radiotherapy and Oncology</i> , 2018 , 126, 368-374 | 5.3 | 17 |
| 162 | Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. <i>Journal of Cancer</i> , 2018 , 9, 1813-1820 | 4.5 | 34 |
| 161 | Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 851-864 | 4 | 4 |
| 160 | Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. <i>Lung Cancer</i> , 2018 , 125, 273-281 | 5.9 | 40 |
| 159 | Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. <i>Genes Chromosomes and Cancer</i> , 2018 , 57, 513-521 | 5 | 9 |
| 158 | Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. <i>Cancer Science</i> , 2018 , 109, 2852-2862 | 6.9 | 9 |
| 157 | Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1138-1139 | 13.4 | 2 |
| 156 | 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9026-9026 | 2.2 | 8 |
| 155 | Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9053-9053 | 2.2 | 3 |
| 154 | Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9071-9071 | 2.2 | 3 |
| 153 | Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9072-9072 | 2.2 | 5 |

| | | | |
|-----|--|------|-----|
| 152 | Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9094-9094 | 2.2 | 8 |
| 151 | Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). <i>Patient</i> , 2018 , 11, 131-141 | 3.7 | 12 |
| 150 | Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 107-116 | 35.1 | 86 |
| 149 | Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. <i>British Journal of Cancer</i> , 2018 , 118, 38-42 | 8.7 | 14 |
| 148 | Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1405-1411 | 2.2 | 152 |
| 147 | Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3101-3109 | 2.2 | 146 |
| 146 | Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2027-2039 | 59.2 | 427 |
| 145 | Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1897-1905 | 8.9 | 45 |
| 144 | Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. <i>Current Oncology Reports</i> , 2017 , 19, 4 | 6.3 | 12 |
| 143 | Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1288-1296 | 2.2 | 363 |
| 142 | Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. <i>Lung Cancer</i> , 2017 , 110, 7-13 | 5.9 | 31 |
| 141 | Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. <i>Oncologist</i> , 2017 , 22, 1075-1083 | 5.7 | 19 |
| 140 | EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1247-1256 | 8.9 | 40 |
| 139 | Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , 2017 , 109, | 9.7 | 136 |
| 138 | Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 633-643 | 8.9 | 82 |
| 137 | EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. <i>British Journal of Cancer</i> , 2017 , 116, 175-185 | 8.7 | 61 |
| 136 | Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 567-572 | 8.9 | 139 |
| 135 | New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. <i>Expert Review of Respiratory Medicine</i> , 2017 , 11, 51-55 | 3.8 | 13 |

| | | | |
|-----|--|------|-----|
| 134 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 324-332.e1 | 4.9 | 26 |
| 133 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 891-902 | 35.1 | 56 |
| 132 | Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 403-407 | 8.9 | 432 |
| 131 | Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 694-695.e2 | 2.2 | 2 |
| 130 | Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4027-4034 | 2.2 | 97 |
| 129 | Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3662-3670 | 2.2 | 18 |
| 128 | Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1588-1594 | 8.9 | 16 |
| 127 | Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Eblockers. <i>Science Translational Medicine</i> , 2017 , 9, | 17.5 | 62 |
| 126 | Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1552-1560 | 8.9 | 55 |
| 125 | Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 663-673 | 10.2 | 16 |
| 124 | The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 194-207 | 8.9 | 132 |
| 123 | Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11506-11506 | 2.2 | 11 |
| 122 | Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2006-2006 | 2.2 | 15 |
| 121 | Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2020-2020 | 2.2 | 54 |
| 120 | Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2069-2069 | 2.2 | 11 |
| 119 | Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8547-8547 | 2.2 | 1 |
| 118 | First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9094-9094 | 2.2 | 11 |
| 117 | A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. <i>Oncotarget</i> , 2017 , 8, 41474-41486 | 3.3 | 12 |

| | | | |
|-----|---|------|-----|
| 116 | Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. <i>Clinical Cancer Research</i> , 2016 , 22, 5130-5140 | 12.9 | 397 |
| 115 | Profile of the theascreen [®] EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1251-1257 | 3.8 | 13 |
| 114 | Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer. <i>Case Reports in Oncology</i> , 2016 , 9, 474-480 ¹ | | 1 |
| 113 | Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016 , 17, e103-e112 | 4.9 | 10 |
| 112 | Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1140-52 | 8.9 | 46 |
| 111 | Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3375-82 | 2.2 | 605 |
| 110 | Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 661-8 | 2.2 | 441 |
| 109 | Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2016 , 94, 46-53 | 5.9 | 48 |
| 108 | First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 370-9 | 8.9 | 11 |
| 107 | Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9002-9002 | 2.2 | 53 |
| 106 | Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9016-9016 | 2.2 | 41 |
| 105 | Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9022-9022 | 2.2 | 14 |
| 104 | Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9044-9044 | 2.2 | 26 |
| 103 | First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9046-9046 | 2.2 | 10 |
| 102 | Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9061-9061 | 2.2 | 8 |
| 101 | Effect of itraconazole or rifampicin on the pharmacokinetics (PK) of osimertinib (AZD9291).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e14100-e14100 | 2.2 | 1 |
| 100 | Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20501-e20501 | 2.2 | 5 |
| 99 | The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. <i>Oncotarget</i> , 2016 , 7, 12404-13 | 3.3 | 165 |

| | | | |
|----|---|------|------|
| 98 | Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20507-e20507 | 2.2 | 1 |
| 97 | TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TP39106-TP39106 | 2.2 | |
| 96 | Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. <i>Journal of Cancer</i> , 2016 , 7, 1515-23 | 4.5 | 5 |
| 95 | Enhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One Helical Cell-Penetrating Peptide or Glutathione and Tween 80. <i>International Journal of Molecular Sciences</i> , 2016 , 17, | 6.3 | 24 |
| 94 | Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Biomedical Science</i> , 2016 , 23, 86 | 13.3 | 35 |
| 93 | AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. <i>Science Translational Medicine</i> , 2016 , 8, 368ra172 | 17.5 | 58 |
| 92 | Safety of gefitinib in non-small cell lung cancer treatment. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 993-1000 | 10.0 | 5 |
| 91 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , 2016 , 17, 577-89 | 21.7 | 691 |
| 90 | First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. <i>Clinical Lung Cancer</i> , 2016 , 17, 150-60 | 4.9 | 12 |
| 89 | Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. <i>Clinical Lung Cancer</i> , 2016 , 17, e77-e94 | 4.9 | 23 |
| 88 | Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4079-4085 | 2.2 | 124 |
| 87 | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncology</i> , 2016 , 17, 1497-1508 | 21.7 | 954 |
| 86 | Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3258-66 | 2.2 | 107 |
| 85 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , 2015 , 16, 141-51 | 21.7 | 1081 |
| 84 | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology</i> , 2015 , 16, 990-8 | 21.7 | 291 |
| 83 | AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1689-99 | 59.2 | 1447 |
| 82 | Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1958-65 | 2.2 | 211 |
| 81 | Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2015 , 27, 94-101 | 4.2 | 102 |

| | | | |
|----|--|-----|-----|
| 80 | Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. <i>Therapeutic Advances in Medical Oncology</i> , 2015 , 7, 274-90 | 5.4 | 18 |
| 79 | The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. <i>Oncologist</i> , 2015 , 20, 1051-7 | 5.7 | 9 |
| 78 | Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 38-45 | 3.6 | 25 |
| 77 | Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. <i>Journal of Thoracic Oncology</i> , 2015 , 10, e95-e96 | 8.9 | 16 |
| 76 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1754-61 | 8.9 | 96 |
| 75 | IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. <i>Oncotarget</i> , 2015 , 6, 10415-31 | 3.3 | 49 |
| 74 | Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. <i>PLoS ONE</i> , 2015 , 10, e0119135 | 3.7 | 34 |
| 73 | Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. <i>Lung Cancer</i> , 2015 , 88, 208-14 | 5.9 | 41 |
| 72 | Angiokinase inhibitors in non-small-cell lung cancer. <i>Clinical Investigation</i> , 2015 , 5, 47-59 | | |
| 71 | Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Therapies. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1715-23 | 8.9 | 74 |
| 70 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 793-799 | 8.9 | 139 |
| 69 | Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. <i>Clinical Lung Cancer</i> , 2015 , 16, 137-43 | 4.9 | 8 |
| 68 | AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8000-8000 | 2.2 | 9 |
| 67 | First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8013-8013 | 2.2 | 17 |
| 66 | AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8016-8016 | 2.2 | 15 |
| 65 | The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major clinical trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8070-8070 | 2.2 | 4 |
| 64 | Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8073-8073 | 2.2 | 4 |
| 63 | The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. <i>PLoS ONE</i> , 2015 , 10, e0145936 | 3.7 | 15 |

| | | | |
|----|--|-----|----|
| 62 | Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19061-e19061 | 2.2 | |
| 61 | TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS8109-TPS8109 | 2.2 | 1 |
| 60 | Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8043-8043 | 2.2 | |
| 59 | First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. <i>European Journal of Cancer</i> , 2014 , 50, 2219-30 | 7.5 | 29 |
| 58 | Reply to E.R. Haspinger et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 863-4 | 2.2 | 0 |
| 57 | Reply to F. De Marinis et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 865 | 2.2 | 0 |
| 56 | Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014 , 15, 173-81 | 4.9 | 50 |
| 55 | Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. <i>Lung Cancer</i> , 2014 , 85, 230-8 | 5.9 | 40 |
| 54 | Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1411-7 | 8.9 | 12 |
| 53 | Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1385-92 | 8.9 | 41 |
| 52 | Interview: Changing advanced lung cancer into chronic disease. <i>Lung Cancer Management</i> , 2014 , 3, 23-28 | 2.6 | 1 |
| 51 | Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1720-5 | 8.9 | 35 |
| 50 | Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1171-9 | 8.9 | 57 |
| 49 | Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). <i>Lung Cancer</i> , 2014 , 83, 174-81 | 5.9 | 36 |
| 48 | Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. <i>Supportive Care in Cancer</i> , 2014 , 22, 1189-97 | 3.9 | 11 |
| 47 | A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014 , 32, 445-51 | 4.3 | 17 |
| 46 | Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8004-8004 | 2.2 | 22 |
| 45 | Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8009-8009 | 2.2 | 63 |

| | | | |
|----|--|------|------|
| 44 | Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8017-8027 | 2.2 | 27 |
| 43 | A phase I dose-defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19013-e19013 | 2.2 | 1 |
| 42 | Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET+), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFR ^{wt}) and progression on gefitinib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS8121-TPS8121 | 2.2 | |
| 41 | Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS2631-TPS2631 | 2.2 | |
| 40 | The impact of diabetes mellitus on early cervical cancer in Bia: A population-based cohort study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16501-e16501 | 2.2 | |
| 39 | Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. <i>Journal of Neuro-Oncology</i> , 2013 , 115, 61-70 | 4.8 | 7 |
| 38 | EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2013 , 9, 991-1003 | 3.6 | 6 |
| 37 | MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. <i>Molecular Oncology</i> , 2013 , 7, 112-20 | 7.9 | 61 |
| 36 | First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. <i>Drugs</i> , 2013 , 73, 357-69 | 12.1 | 12 |
| 35 | Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. <i>Lung Cancer</i> , 2013 , 82, 420-5 | 5.9 | 32 |
| 34 | Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3327-34 | 2.2 | 2262 |
| 33 | Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3342-50 | 2.2 | 222 |
| 32 | A selective ALK inhibitor in ALK-rearranged patients. <i>Lancet Oncology, The</i> , 2013 , 14, 564-5 | 21.7 | 6 |
| 31 | Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2013 , 14, 418-24 | 4.9 | 17 |
| 30 | Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2013 , 49, 106-14 | 7.5 | 19 |
| 29 | ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Cancer Letters</i> , 2013 , 328, 144-51 | 9.9 | 106 |
| 28 | Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy. <i>Clinical Cancer Research</i> , 2013 , 19, 5292-9 | 12.9 | 10 |
| 27 | Diarrhea associated with afatinib: an oral ErbB family blocker. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 729-36 | 3.5 | 73 |

| | | | |
|----|---|------|-----|
| 26 | ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3926-34 | 2.2 | 134 |
| 25 | Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 595-605 | 9.7 | 402 |
| 24 | Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). <i>Journal of Thoracic Oncology</i> , 2013 , 8, 229-37 | 8.9 | 57 |
| 23 | Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. <i>PLoS ONE</i> , 2013 , 8, e80276 | 3.7 | 22 |
| 22 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. <i>Lancet Oncology</i> , 2012 , 13, 539-48 | 21.7 | 331 |
| 21 | Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. <i>Lancet Oncology</i> , 2012 , 13, 528-38 | 21.7 | 777 |
| 20 | Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2012 , 77, 346-52 | 5.9 | 22 |
| 19 | Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 433-40 | 2.2 | 420 |
| 18 | Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E2127-33 | 11.5 | 366 |
| 17 | Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. <i>Journal of Magnetic Resonance Imaging</i> , 2012 , 36, 387-96 | 5.6 | 42 |
| 16 | Survival following surgery with or without adjuvant chemotherapy for stage I-IIIa non-small cell lung cancer: an east asian population-based study. <i>Oncologist</i> , 2012 , 17, 1294-302 | 5.7 | 10 |
| 15 | Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 973-81 | 8.9 | 49 |
| 14 | Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. <i>Clinical Cancer Research</i> , 2012 , 18, 3470-7 | 12.9 | 46 |
| 13 | Survival of patients with small cell lung carcinoma in Taiwan. <i>Oncology</i> , 2012 , 82, 19-24 | 3.6 | 21 |
| 12 | Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/ gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator choice chemotherapy following progression on afatinib monotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7557-7557 | 2.2 | 11 |
| 11 | Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/ gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7558-7558 | 2.2 | 3 |
| 10 | LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA7500-LBA7500 | 2.2 | 12 |
| 9 | LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA7500-LBA7500 | 2.2 | 53 |

| | | | |
|---|---|------|------|
| 8 | Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. <i>Translational Lung Cancer Research</i> , 2012 , 1, 227-9 | 4.4 | |
| 7 | Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations. <i>Drugs</i> , 2011 , 71, 79-88 | 12.1 | 6 |
| 6 | INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. <i>BMC Cancer</i> , 2011 , 11, 430 | 4.8 | 59 |
| 5 | Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1663-9 | 8.9 | 35 |
| 4 | Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1418-25 | 8.9 | 51 |
| 3 | Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1872-80 | 8.9 | 106 |
| 2 | Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). <i>Journal of Clinical Oncology</i> , 2011 , 29, 2866-74 | 2.2 | 1102 |
| 1 | Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. <i>Clinical Cancer Research</i> , 2011 , 17, 6459-66 | 12.9 | 53 |